ERBB2 and ovarian neoplasm: Figure 5A shows that the mPEG × HER2-modified PLD can significantly inhibit the HER2+ ovarian tumor growth as compared to treatment with mPEG × DNS-modified PLD (P = 0.0319) or PLD (P = 0.0437) and there was no significant difference between mPEG × DNS-modified PLD- and PLD-treated groups (P = 0.5754) (Fig. 5A).